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The aim of this study was to determine the impact of HRCT-confirmed emphysema on
biomarkers evaluating airway and systemic inflammation in COPD patients.
Forty-nine consecutive male COPD outpatients with stable COPD were divided in two groups
according to the presence or absence of emphysema on HRCT. Patients underwent pulmonary
function tests, plus assessment of exercise capacity, body composition and quality of life.
Biomarkers were measured in serum (CRP, interleukin-6, TNF-a, leptin, adiponectin, osteocal-
cin, insulin growth factor-1, and systemic oxidative stress), in plasma (fibrinogen and VEGF)
and in whole blood (B-type natriuretic peptide). TNF-a, 8-isoprostane and pH were additionally
measured in exhaled breath condensate.
Patients with emphysema had more severe lung function impairment, lower body-mass
index and fat-free mass index, and poorer quality of life. Additionally, they presented
increased systemic oxidative stress and plasma fibrinogen and lower BNP compared to patients
without emphysema. After proper adjustment for disease severity, all differences remained
with the exceptions of body-mass index, fat-free mass index and BNP.
COPD patients with HRCT-confirmed emphysema present increased systemic oxidative stress
and fibrinogen, suggesting that they may be more prone to the systemic consequences of COPD
compared to patients without emphysema.
ª 2009 Elsevier Ltd. All rights reserved.Medicine Department, University of Thessaly Medical School, University Hospital of Larissa, Larissa
.
Kostikas).
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Study designChronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation that is not fully reversible,
usually progressive, and associated with an abnormal
inflammatory response of the lungs in response to noxious
particles and gases.1 COPD is associated with both airway
and systemic inflammation.2 Airway inflammatory markers
are higher in more severe disease and increase during COPD
exacerbations.2 There is evidence that systemic inflam-
mation is present even in stable COPD and the intensity of
the inflammatory process may be related to the severity of
the underlying disease.3 Recently it has been suggested
that COPD might be a part of a chronic systemic inflam-
matory syndrome.4 Several systemic inflammatory markers,
such as C-reactive protein (CRP) and fibrinogen, are
increased in patients with COPD both in stable disease and
in exacerbations.2,5e7
The two major subtypes, chronic bronchitis and
emphysema, lead in the two clearly distinguishable
phenotypes of the ‘‘blue bloater’’ and the ‘‘pink puffer’’.
Despite the fact that emphysema can occur in both
phenotypes, it is more frequently observed in the ‘‘pink
puffer’’ phenotype.8 The introduction of high resolution
computed tomography (HRCT) has brought a new dimension
to the study of COPD, as it offers the opportunity to study
the pathologic processes involved in structural changes
within the lung and to investigate the severity, extension
and distribution of emphysema.9,10 Besides the well-
studied aforementioned features of the two phenotypes,
recent studies have evaluated differences between
patients with and without emphysema on HRCT, reporting
that COPD patients with HRCT-confirmed emphysema are
characterized by more severe lung function impairment,
more intense airway inflammation as evaluated by induced
sputum, and possibly more serious systemic dysfunction.11
However, possible differences in biomarkers of airway and
systemic inflammation have not been fully evaluated in
relation to the presence of emphysema.
The aim of the present study was to determine the
impact of the presence of HRCT-confirmed emphysema on
biomarkers that have been previously used to evaluate
airway and systemic inflammation in patients with COPD.
Health-related quality of life, body composition, and lung
function were additionally assessed in patients with and
without emphysema, and correlations with local and
systemic inflammatory biomarkers were evaluated.Materials and methods
Subjects
Detailed methodology is provided in the Supplementary
material. We enrolled 49 consecutive male outpatients with
stable COPD. Patients with significant comorbidities,
including cardiovascular disease, were meticulously
excluded. No patient was receiving any form of cortico-
steroids 4 weeks prior to samples collection. The study
protocol was approved by the local ethics committee and
patients provided written informed consent.Exhaled breath condensate (EBC) was collected using
a commercial condenser (EcoScreen, Viasys, Germany).12
Blood was centrifuged at 1500 g for 15 min at 4 C and
samples were stored at 80 C. Arterial blood gases were
measured using a commercial analyser (Instrumentation
Laboratories, Milan, Italy). Patients were subsequently
submitted to: (a) Pulmonary function tests with a commer-
cially available system (Master Screen, Erich Jaeger GmbH,
Wuerzburg, Germany).13 (b) Assessment of body composi-
tion with Bioelectrical Impedance Analysis (BIA 101 System
Analyser, Akern, Florence, Italy)14,15; body mass index (BMI)
was calculated as weight/height squared and fat-free mass
index (FFMI) was calculated as FFM/height squared.16 (c)
Evaluation of exercise capacity with the 6-minute walk
test.17 (d) Chest high resolution computed tomography
(HRCT) using either a Somaton HiQ or a Somaton Plus
scanner (Siemens, Erlanger, Germany). The degree of
emphysema was calculated using a visual emphysema score
as previously described.18 The presence of emphysematous
lesions involving 15% of the pulmonary parenchyma were
used for the characterization of the emphysematous
phenotype, as previously described in COPD.11 Dyspnea was
assessed with the modified Medical Research Council (MRC)
scale19 and BODE index was determined.20 HRQoL was
assessed with Saint George’s Respiratory Questionnaire.21
Patients were additionally submitted to echocardiography
by an experienced cardiologist (E.Z.) to exclude cardio-
vascular comorbidities.
Measurements of biomarkers
Serum CRP and plasma fibrinogen were quantified by
immunonephelometry (Behring Nephelometer Analyzer-II).
Serum IL-6 and TNF-a and plasma VEGF levels were
measured using commercial ELISA kits (Biosource Europe,
Nivelles, Belgium). B-type natriuretic Peptide (BNP) was
measured with a commercial analyzer (Triage BNP test,
BIOSITE, California USA). Serum leptin and adiponectin
levels were measured using human radioimmunoassay kits
(KIPMR44, Biosource Europe SA, Belgium; and LINCO
Research, USA, respectively). Serum human osteocalcin and
insulin growth factor-1 (IGF-1) levels were measured using
human immunoradiometric assay kits (KIP1381, Biosource
Europe SA, Belgium; and IGF1-RIACT, CIS bio-international,
France, respectively). Serum oxidative stress was measured
with a commercially available method, that measures total
hydroperoxides, expressed in conventional units (Carratelli
units, UCarr, 1 UCarr corresponds to 0.8 mg/L H2O2; d-ROMs
test; Diacron; Grosseto, Italy).22,23
EBC pH was measured after Argon deaeration, as previ-
ously described.24 EBC TNF-a and 8-isoprostane were
measured with commercial ELISA kits (Biosource Europe,
Nivelles, Belgium; and Cayman Chemical, Ann Arbor, MI
respectively).
Statistical analysis
Data are expressed as mean SD or as median (inter-
quartile ranges) for normally distributed and skewed data,
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patients with and without emphysema were performed
with ManneWhitney U and unpaired Student’s t-tests for
skewed and normally distributed variables, respectively.
Correlations were assessed using Spearman’s and Pearson’s
correlation coefficients for skewed and normally distrib-
uted variables, respectively. P values <0.05 were consid-
ered statistically significant. Analysis was performed with
SPSS 15 (SPSS, Chicago, IL).
Results
Subjects were divided into two groups according to their
emphysema score in HRCT. Patients without significant
emphysema (nZ 25) had a HRCT emphysema score of 0 (0,
0.2), whereas patients with HRCT-confirmed emphysema
(nZ 24) had a score of 2.8 (1.12, 3.47).
Characteristics of study subjects according to the
presence of emphysema in HRCT (Table 1)
There was no difference in age and smoking history between
the two groups. However, patients with emphysema hadTable 1 Characteristics of COPD patients according to the pres
Non emphysema (nZ 2
Age (years) 66.6 9.6
Pack-years 49.6 15.7
Current smokers 13/25
MMRC 2.0 (1, 2)
PaO2 (mmHg) 76.5 9.1
PaCO2 (mmHg) 38.4 4.3
FEV1 (% pred.) 61.1 12.7
FVC (% pred.) 77.3 12.4
FEV1/FVC 60.4 7.8
FRC (% pred.) 136.8 21.6
RV (% pred.) 143.1 33.5
IC(% pred.) 86.2 15.3
TLC(% pred.) 100.5 (95.9, 110.1)
RV/TLC(% pred.) 131.7 17.4
IC/TLC(% pred.) 0.38 0.09
DLCO(mmol/min/kPa) 83.8 13.6
DLCO/VA(mmol/min/kPa/L) 93.2 15.4
SGRQ total 30.9 12.9
SGRQ symptoms 32.5 18.1
SGRQ activity 46.2 20.9
SGRQ impact 21.9 13.4
6MWD (m) 400.7 54
DSat (%) 1.0 (0.0, 2.0)
DBorg 1.0 (1.0. 2.0)
BODE index 2.0 (1.0, 2.0)
BMI kg/m2 27.3 3.8
FFMI kg/m2 18.6 (17.7, 20.2)
Values are reported as mean SD or median (interquartile ranges) fo
MMRC: modified Medical Research Council; FRC: functional residual c
ratory capacity; FEV1: forced expiratory volume in 1 s; FVC: forced vit
Saint George respiratory questionnaire; BMI, body mass index; FFMI: Fa
in oxygen saturation after the 6MWT, DBorg: alteration in the level of
mass index, airflow obstruction, dyspnea, exercise performance.lower FEV1 and FEV1/FVC ratio and worse diffusing capacity
for carbon monoxide (DLco). Furthermore, TLC and RV did
notdiffer between the twogroups (despite a significant trend
in the latter), but patients with emphysema had lower IC/
TLC ratio (Fig. 1a) andhigher RV/TLC ratio. Therewas a trend
for lower exercise capacity, as expressed by the total
distance walked in 6 min that did not reach statistical
significance. Moreover, patients with emphysema had worse
MRCdyspnea score (Fig. 1b), and higher BODE index (Fig. 1c).
Additionally, patients with emphysema had lower BMI and
FFMI compared to patients without significant emphysema
(Fig. 2). Finally, patients with emphysema had a higher SGRQ
total score, reflecting worse HRQoL (Fig. 3). This difference
reflected mainly differences in the activity score and the
impact in daily living, whereas no differencewas observed in
the symptoms score.
Differences of biomarkers according to the
presence of emphysema in HRCT (Table 2)
Patients with emphysema had higher levels of systemic
oxidative stress (pZ 0.005) (Fig. 4a), lower circulating BNP
levels (pZ 0.025) (Fig. 4b), and higher plasma fibrinogen
levels (pZ 0.006) (Fig. 4c). A trend for higher TNF-a levelsence or absence of emphysema in HRCT.
5) Emphysema (nZ 24) p value
65.4 8.9 0.589
60.6 26.9 0.174
11/24 0.886
2.5 (2, 3) 0.004
71.6 9.7 0.112
39.5 6.5 0.774
42.3 17.3 <0.001
62.9 16.1 0.003
52.6 11.1 0.016
156.8 45.8 0.066
187.3 87.3 0.063
67.3 17.8 0.001
103.0 (91.1, 130.2) 0.633
156.4 35.7 0.008
0.27 0.09 0.001
51.0 18.9 <0.001
62.9 24.4 <0.001
47.0 19.9 0.005
41.3 21.5 0.084
63.7 24.8 0.021
39.4 20.2 0.002
336.0 116.5 0.068
3.0 (0.75, 4.0) 0.108
1.0 (0.0, 3.0) 0.639
5.0 (2..0, 6.0) 0.001
25.0 3.5 0.041
16.4 (15.2, 19.6) 0.041
r normally distributed and skewed data, respectively.
apacity; RV: residual volume; TLC: Total lung capacity; IC: inspi-
al capacity; DLCO: diffusing capacity for carbon monoxide; SGRQ:
t Free Mass index; 6MWD: 6 min walking distance; DSat: alteration
dyspnea according to the Borg scale after the 6MWT, BODE: body
Figure 1 (A) Inspiratory capacity to total lung capacity ratio
(IC/TLC), (B) Medical Research Council dyspnea scale, and
(C) BODE index, in patients with COPD according to the pres-
ence or absence of emphysema on HRCT. Subjects with HRCT
confirmed emphysema had higher BODE index, experienced
worse dyspnea, and had lower IC/TLC ratio compared to
subjects without HRCT confirmed emphysema. A: Data are
presented as mean. B and C: Values are reported as median
(interquartile ranges).
Figure 2 Fat free mass index (FFMI) in patients with COPD
according to the presence or absence of emphysema on HRCT
Subjects with HRCT confirmed emphysema have lower FFMI
compared to subjects without HRCT confirmed emphysema.
Values are reported as median (interquartile ranges).
Figure 3 Saint George’s Respiratory Questionnaire (SGRQ)
total score, along with symptoms, activity and impact scores,
in patients with COPD according to the presence or absence of
emphysema on HRCT. Subjects with HRCT confirmed emphy-
sema have higher total score, activity score and impact score
in the SGRQ compared to subjects without HRCT confirmed
emphysema. However, no significant different was observed in
the symptoms score between the two study groups. Data are
presented as means.
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statistical significance. No other significant differences
were observed in the other biomarkers in blood or EBC that
were examined between the two study groups.
Correlations between HRCT emphysema score and
functional and clinical parameters in COPD patients
Significant correlations between HRCT emphysema score
and functional and clinical parameters in COPD patients are
shown in Table 3. The HRCT emphysema score presentedsignificant correlations with virtually all functional param-
eters (dynamic and absolute lung volumes and diffusing
capacity of the lung), and the measurements of body
composition (BMI and FFMI). Furthermore, HRCT emphy-
sema score presented significant correlations with HRQoL
and exercise capacity in COPD patients. None of the
biomarkers measured in blood samples or EBC presented
significant correlations with the HRCT emphysema score.
Evaluation of significant differences according to
disease severity
According to our observations, COPD patients with HRCT
confirmed emphysema had more severe disease as assessed
Table 2 Levels of biological markers in patients with COPD according to the presence or absence of emphysema on HRCT
examination.
Marker Non emphysema (nZ 25) Emphysema (nZ 24) p value
EBC pH 6.99 0.38 6.87 0.32 0.378
EBC 8-isoprostane (pg/ml) 3.50 (2.68, 6,58) 4.10 (3.07, 5.50) 0.693
EBC TNF-a (pg/ml) 21.00 (20.0, 22.79) 20.00 (20.00, 21.77) 0.209
Serum CRP (mg/dl) 0.20 (0.10, 0.35) 0.30 (0.10, 0.40) 0.675
Serum TNF-a(pg/ml) 37.03 (32.0, 43.42) 41.12 (34.83, 48.37) 0.074
Serum IL-6 (pg/dl) 8.70 (7.45, 11.50) 11.55 (7.52, 13.60) 0.177
Serum BNP (pg/ml) 31.40 (14.67, 69.82) 11.15 (6.85, 25.65) 0.025
Serum Oxidative Stress (UCARR) 235.00 (200.00, 281.00) 282.00(252.25, 344.75) 0.005
Plasma VEGF (pg/ml) 54.6 17.0 60.6 18.2 0.200
Plasma Fibrinogen (mg/dl) 406.00 (350.00, 461.00) 503.00 (430.50, 567.00) 0.006
Serum Adiponectin (ng/ml) 16.88 6.23 18.44 9.76 0.773
Serum Leptin (ng/ml) 4.49 2.86 4.00 2.77 0.529
Serum Leptin/Adiponectin 0.27(0.10, 0.44) 0.18 (0.10, 0.49) 0.812
Serum IGF-1 (ng/ml) 101.80 (87.45, 156.50) 119.50 (88.60, 188.4) 0.464
Serum Osteocalcin (ng/ml) 7.20 4.28 5.68 3.57 0.183
Values are reported as mean SD or median (interquartile ranges) for normally distributed and skewed data, respectively.
EBC: exhaled breath condensate, TNF-a: Tumour necrosis factor a, CRP: C-reactive protein, IL-6: interleukin 6, BNP: B-type natriuretic
Peptide, VEGF: vascular endothelial growth factor, IGF-1: insulin-like growth factor.
Inflammation in COPD phenotypes 279by FEV1. In order to ascertain whether the observed
differences between the two study groups were due to the
presence of emphysema itself or due to the presence of
more severe disease, a multivariate linear regression model
was performed using the clinical and laboratorial parame-
ters that presented significant differences between the two
groups as the outcome, and FEV1 as a covariate. After
adjustment for FEV1, the two study groups still differed in
all functional characteristics which have been previously
reported as well as in serum oxidative stress (pZ 0.044)
and plasma fibrinogen (pZ 0.006). However, patients with
and without HRCT confirmed emphysema did not differ in
BNP, BMI and FFMI levels (pZ 0.153, pZ 0.252, and
pZ 0.095, respectively).
Discussion
In the present study we have shown that COPD patients
with HRCT-confirmed emphysema present worse pulmonary
function, higher BODE index, worse dyspnea and health
related quality of life, and lower BMI and FFMI, compared
to COPD patients without emphysema. Patients with
emphysema also had higher systemic oxidative stress and
plasma fibrinogen levels and lower BNP levels compared to
patients without emphysema. However, when adjusted for
FEV1, the two study groups did not differ in BNP levels, in
BMI and in FFMI, whereas the rest of the differences
remained, including the increased levels in systemic
oxidative stress and plasma fibrinogen. This is the first study
to our knowledge that addresses the issue of local and
systemic biomarkers of inflammation in patients with HRCT-
confirmed emphysema.
We confirm previous data reporting that COPD patients
with HRCT-confirmed emphysema have worse pulmonary
function.11 In our study we have also shown that COPD
patients with HRCT-confirmed emphysema have worse
HRQoL, as expressed by the total score in SGRQ. Having in
mind that the minimal clinically important difference in theSGRQ is a change of 4 units,25 patients with emphysema
experience greater limitations in everyday living since the
difference between the two COPD phenotypes is almost 16
units. Unlike a recent study reporting that patients with
emphysema differed in all parameters of SGRQ,26 no
significant difference was found in the symptoms score
between the two groups of patients in our study. The above
findings lead to the hypothesis that other factors apart from
symptoms influence HRQoL in patients with emphysema.
A factor that has been reported to be related to HRQoL in
COPD patients is the frequency of exacerbations.27
However, our study groups did not differ in exacerbation
frequency as assessed by their medical records, although
we have to admit that a recollection bias may exist at this
point, since those data were retrospectively collected. On
the other hand, it is well known that depression is
a common comorbidity in patients with COPD, especially in
patients with more severe disease,28 and this may
contribute to worse HRQoL in patients with emphysema.
Oxidative stress is a central feature in the pathogenesis
of COPD.29 Patients with emphysema presented no differ-
ence in EBC 8-isoprostane, a biomarker of lipid perox-
idation that has been previously found elevated in COPD
patients.30 In contrast, systemic oxidative stress was
significantly higher and serum TNF-a presented a trend to
be elevated in patients with emphysema. A possible reason
for the discrepancy between total systemic oxidative stress
and other biomarkers of local and systemic inflammation in
our study could be the fact that the method that we have
used for the assessment of oxidative stress expresses the
total oxidant burden in the body and is not specific for
a solely marker of oxidative stress,31 in contrast to the rest
of the biomarkers that express specific aspects of inflam-
mation. The fact that COPD patients with HRCT confirmed
emphysema have higher levels of systemic oxidative stress,
supports the hypothesis that the presence of emphysema is
related to the action of free radicals outside the lung,32
that is involved in the pathogeneses of muscle loss and
Figure 4 (A) Serum oxidative stress (B) B-type natriuretic
peptide (BNP) and (C) plasma fibrinogen in patients with COPD
according to the presence or absence of emphysema on HRCT.
Subjects with HRCT confirmed emphysema had higher serum
oxidative stress levels, lower circulating BNP levels and higher
plasma fibrinogen concentrations, compared to subjects
without HRCT confirmed emphysema Values are reported as
median (interquartile ranges).
Table 3 Significant correlations between emphysema
score in HRCT and functional and clinical parameters in
COPD patients.
r value p value
MRC dyspnea scale 0.420 0.003
FRC 0.524 <0.001
RV 0.573 <0.001
TLC 0.493 0.001
RV/TLC 0.575 <0.001
FRC/TLC 0.324 0.03
IC 0.500 0.001
IC/TLC 0.662 <0.001
FEV1 0.640 <0.001
FVC 0.478 <0.001
FEV1/FVC 0.506 <0.001
DLCO 0.843 <0.001
SGRQ total 0.670 <0.001
SGRQ symptoms 0.350 0.019
SGRQ activity 0.595 <0.001
SGRQ impact 0.671 <0.001
BMI 0.331 0.02
FFMI 0.321 0.028
6MWD  0.471 0.001
BODE 0.683 <0.001
MMRC: modified Medical Research Council; FRC: functional
residual capacity; RV: residual volume; TLC: Total lung
capacity; IC: inspiratory capacity; FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; DLCO: diffusing
capacity for carbon monoxide; SGRQ: Saint George respiratory
questionnaire; BMI, body mass index; FFMI: Fat Free Mass index;
6MWD: 6 min walking distance; BODE: body mass index, airflow
obstruction, dyspnea, exercise performance.
280 A.I. Papaioannou et al.dysfunction in COPD patients,32 while systemic inflamma-
tion causes nutritional abnormalities and weight loss.33 Our
data support the hypothesis that higher systemic levels of
oxidative stress in COPD patients may contribute to the
lower BMI and FFMI and the trend for impaired exercise
capacity in those patients.
Cardiovascular comorbidities are common in COPD
patients and represent a significant cause of mortality.34
Elevated CRP and fibrinogen levels have been associated
with greater cardiovascular mortality in COPD.35,36 SerumCRP levels did not differ between the two COPD phenotypes
in our study, where patients with significant cardiovascular
disease were meticulously excluded. However, the higher
plasma fibrinogen levels in patients with emphysema could
lead to the hypothesis that these patients might be at
greater cardiovascular risk. In contrast, BNP levels were
more elevated in patients without emphysema. BNP has
been proposed as a non-invasive marker for the presence
and severity of pulmonary hypertension in chronic lung
disease.37 A recent study has also shown that BNP levels
were elevated in COPD patients with cor pulmonale.38
Based on the above, we hypothesize that increased BNP
levels in non-emphysematous COPD patients may represent
higher risk for development of pulmonary hypertension and
cor pulmonale, as in the ‘‘blue-bloater’’ phenotype.
However, according to the fact that BNP levels did not
differ in the two study groups when our data were cor-
rected for FEV1 one can hypothesize that the risk for the
development of pulmonary hypertension in COPD patients
is more closely associated with disease severity.
Nutritional abnormalities, such as weight loss and skel-
etal muscle loss and dysfunction, are common conse-
quences of COPD.33 In this study we have shown that
patients with emphysema have lower BMI and FFMI
compared to non emphysematous COPD patients. A recent
study has shown that FFM decline in COPD patients is
associated with worse lung function.39 Furthermore, FFMI
reflects better the skeletal muscle mass in patients with
Inflammation in COPD phenotypes 281COPD and has been recently shown to correlate to dyspnea,
airway obstruction and exercise capacity.40 Interestingly,
though, neither BMI nor FFMI differed between our study
groups when values were corrected for FEV1. That obser-
vation also leads to the plausible hypothesis that both low
BMI and low FFMI in our COPD patients with emphysema
were associated to disease severity.
Leptin and adiponectin are adipose tissue hormones
which have been found to be altered in COPD patients.41,42
We found no difference in their levels between patients with
and without emphysema, despite the significant difference
in BMI and FFMI.41,42 One possible explanation could be that
those hormones may be also be involved in the systemic
inflammation of COPD.43 Insulin-like growth factor (IGF-1) is
a peptide that normally supports muscle structure and
function, that may be implicated in the development of
muscle weakness in COPD.44 COPD patients present
decreased serum IGF-1 concentrations45 and that those
concentrations correlate to muscle strength.44 The absence
of significant difference in IGF-1betweenCOPDpatientswith
and without emphysema, despite a difference in FFMI,
supports the hypothesis that muscle dysfunction, and not
only the amount of muscle mass, is important in COPD.
The incidence of osteopenia and osteoporosis is
increased in COPD, being invariably present in patients with
low BMI and FFMI.46 Osteocalcin, a hormone produced by
osteoblasts, is considered a biomarker of bone density,47
being decreased in COPD patients receiving treatment with
corticosteroids.48,49 No significant difference was found in
serum osteocalcin levels between patients with and
without emphysema, despite the lower BMI and FFMI in the
former. Possible differences in the use of corticosteroids in
our patients may account for this discrepancy. Further
studies in steroid naive patients with additional use of bone
density measurements are needed in order to evaluate
properly osteocalcin levels in the two phenotypes.
Our study presents several limitations. First, about half
of the patients in each group were current smokers.
However, comparisons in functional and clinical charac-
teristics and biomarkers between current and ex-smokers
did not reveal any significant differences (data not shown).
Second, we excluded patients with significant cardiovas-
cular comorbidities. However, we believe that the exclu-
sion of those patients was important for the proper
evaluation of biomarkers of systemic inflammation in the
two phenotypes. Finally, we have used an observational
method for the quantification of emphysema in HRCT,
instead of special CT software. However, this method
presents excellent correlation with densitometric quanti-
tation18 and can be performed in everyday clinical practice.
In conclusion, we have shown that COPD patients with
HRCT-confirmed emphysema have more severe lung func-
tion impairment, lower BMI and FFMI and poorer HRQoL.
Additionally, they present elevated systemic oxidative
stress and plasma fibrinogen and lower BNP compared to
COPD patients without emphysema. The fact that patients
with emphysema had higher levels of systemic oxidative
stress and plasma fibrinogen even after adjustment for
disease severity, suggests that they may be more prone to
the systemic consequences of COPD compared to patients
without emphysema. Our study further supports that the
optimal characterization of COPD phenotypes may lead tobetter prediction of prognosis and individualization of
treatment in the future.
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